Entrectinib
Indication: for the treatment of adult and pediatric patients (12 years of age and older in the US; 1 month and older in the EU) with solid tumors that are NTRK gene fusion-positive.
Larotrectinib
Indication: For the treatment of adult and pediatric patients with colorectal cancer (CRC) that displays a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Bevacizumab
Indication: First-line treatment of metastatic colorectal cancer (mCRC) in patients with metastatic colon or rectal cancer. It is used in combination with fluoropyrimidine-based chemotherapy as part of initial systemic treatment. Patients may also receive bevacizumab through biosimilars including MVasi (Amgen), Zirabev (Pfizer), and Alymsys (JAMP Pharma).
Irinotecan
Indication: To treat metastatic colorectal cancer (mCRC) and is most commonly used in combination with 5-fluorouracil and leucovorin as part of the FOLFIRI regimen, either as first-line treatment or after prior therapy. It may also be used as monotherapy after progression on fluoropyrimidine-based treatment and is included in the FOLFOXIRI ...
Oxaliplatin
Indication: For the treatment of colorectal cancer in both the adjuvant and metastatic settings. It is commonly used in combination with 5-fluorouracil and leucovorin (FOLFOX) or capecitabine (CAPOX/XELOX) for the treatment of stage III colon cancer after surgical resection and for metastatic colorectal cancer (mCRC) as first-line or subsequent therapy. ...
Leucovorin
Indication: Indicated as a modulating agent used in combination with fluorouracil-based chemotherapy for colorectal cancer in both adjuvant and metastatic settings. It is most commonly administered with 5-fluorouracil as part of regimens such as FOLFOX and FOLFIRI to enhance the antitumour activity of fluorouracil in the treatment of stage III ...
Capecitabine
Indication: Used to treat colorectal cancer in both the adjuvant and metastatic settings. It is used as a single agent (monotherapy) for stage III colon cancer after surgical resection and in combination regimens such as CAPOX (capecitabine plus oxaliplatin) for the treatment of stage III colon cancer and metastatic colorectal ...
5-Fluorouracil (5-FU)
Indication: Used for the treatment of colorectal cancer, primarily in combination with other chemotherapy agents for both adjuvant and metastatic settings. It is commonly used with leucovorin to enhance antitumor activity and forms the backbone of standard regimens such as FOLFOX (5-FU/leucovorin/oxaliplatin), FOLFIRI (5-FU/leucovorin/irinotecan), and FOLFOXIRI.
Panitumumab
Indication: Metastatic colorectal cancer (mCRC) patients with left-sided primary tumours that express wild-type RAS (In combination with chemotherapy) First-Line Treatment: In combination with chemotherapy (e.g., FOLFOX) for newly diagnosed metastatic colorectal cancer that is RAS wild-type, particularly for left-sided tumors. Later-Line Treatment (Monotherapy): For patients whose cancer has progressed after receiving fluoropyrimidine, ...
Trifluridine/tipiracil
Indication Treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents. Lonsurf monotherapy is indicated for the treatment of adult patients with metastatic gastric ...
